Zagotenemab (MAPT) - Research Grade Biosimilar
Product Specifications
Background
Zagotenemab is an antibody drug that targets TAU protein, and has started Phase II clinical trial in April 2018.
Immunogen
Humanized / MAPT [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Neuroscience
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Other Product Names
LY-3303560
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1436660-01 0.02 mg (E-Coli)
Recombinant Bordetella avium Shikimate kinase (aroK)
Sign In for Pricing
View Details MBS1436660-02 0.1 mg (E-Coli)
Recombinant Bordetella avium Shikimate kinase (aroK)
Sign In for Pricing
View Details MBS1436660-03 0.02 mg (Yeast)
Recombinant Bordetella avium Shikimate kinase (aroK)
Sign In for Pricing
View Details MBS1436660-04 0.1 mg (Yeast)
Recombinant Bordetella avium Shikimate kinase (aroK)
Sign In for Pricing
View Details